Stockreport

Lung Disease Focused AN2 Therapeutics' Lackluster Data Prompts To Stop Phase 3 Study Of Lung Infection Candidate, Halves Workforce [Yahoo! Finance]

AN2 Therapeutics, Inc.  (ANTX) 
US:NYSE Investor Relations: ir.antheminc.com
PDF on top of an optimized background regimen (OBR) in treatment-refractory mycobacterium avium complex (MAC) lung disease The Phase 2 part of the study met its primary ob [Read more]